AU2021229984B2 - PSMA combiner and use thereof - Google Patents

PSMA combiner and use thereof Download PDF

Info

Publication number
AU2021229984B2
AU2021229984B2 AU2021229984A AU2021229984A AU2021229984B2 AU 2021229984 B2 AU2021229984 B2 AU 2021229984B2 AU 2021229984 A AU2021229984 A AU 2021229984A AU 2021229984 A AU2021229984 A AU 2021229984A AU 2021229984 B2 AU2021229984 B2 AU 2021229984B2
Authority
AU
Australia
Prior art keywords
psma
cooh
hynic
compound
mtc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021229984A
Other versions
AU2021229984A1 (en
Inventor
Chang Liu
Shaoli SONG
Xiaoping Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiya Pharmaceutical Inc
Original Assignee
Shiya Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiya Pharmaceutical Inc filed Critical Shiya Pharmaceutical Inc
Publication of AU2021229984A1 publication Critical patent/AU2021229984A1/en
Assigned to Shiya Pharmaceutical, Inc reassignment Shiya Pharmaceutical, Inc Request for Assignment Assignors: SHANGHAI FO ZE MEDICAL TECHNOLOGY CO., LTD
Application granted granted Critical
Publication of AU2021229984B2 publication Critical patent/AU2021229984B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Confectionery (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A prostate specific membrane antigen (PSMA) combining compound, a radioactive isotope complex thereof, and the use thereof in nuclear medicine as a tracer and an imaging agent for different disease states of prostate cancer.

Description

PATENT Attorney Docket No.: PWWEP220040-MO
TITLE PSMA BINDER AND USE THEREOF
Background of the Present Disclosure
FIELD OF DISCLOSURE
[0001] The present invention relates to a radioisotope-labeled prostate specific membrane antigen (PSMA) binding compound, and precursor compounds thereof. The compound is applied as a tracer and an imaging agent in nuclear medicine to visualized various disease states of prostate cancer.
DESCRIPTION OF RELATED ARTS
[0002] Prostate cancer (PCa) is the second most common cancer for men worldwide, and its mortality rate ranks fifth among male cancers. There were nearly 400,000 deaths worldwide due to PCa in 2018. Metastasis, recurrence, and resistance to androgen therapy are the leading causes of death for prostate cancer patients. Currently, there is a lack of effective diagnostic methods and therapeutic regimens for metastatic, recurrent and androgen therapy-resistant prostate cancer. Traditional anatomical imaging methods such as computed tomography (CT), magnetic resonance (MR) imaging, and ultrasound all have significant defects. Molecular imaging allows understanding of tumor physiology at 18 the molecular level, enabling more precise prognosis and efficacy monitoring. F-labeled deoxyglucose (FDG) is the most commonly used clinical molecular imaging probe, but 18 F-FDG PET/CT has limited diagnostic value for PCa due to the relatively low metabolism
of PCa.
[0003] At present, other radioactive molecular imaging tracers are being explored clinically
to detect PCa, including radiolabeled choline drugs 1(1 C-choline), radiolabeled acetate (11C-acetate), radiolabeled testosterone (18F-FDHT), anti-1-amino-3-[ 18 F]fluorocyclobutane-1-carboxylic acid ( 1 8F-FACBC) and 1-(2-deoxy-2-[ 18F]-fluoro-L-arabinofuranosyl)-5-thymine (18F-FMAU) and the like. They
PATENT Attorney Docket No.: PWWEP220040-MO
each reflect prostate cancer status through different mechanisms, but none of them is ideal (i.e., easy to synthesis, minimal urinary metabolism, and with tumor-specific uptake).
[0004] Prostate specific membrane antigen (PSMA) is a protein that is highly specifically expressed on the surface of prostate cancer cells, and its expression is further elevated in metastatic hormone-resistant PCa. Due to metastatic hormone-resistant PCa has a high degree of malignancy, poor prognosis, and is an inevitable stage of PCa development, PSMA is an excellent target in the diagnosis and treatment of PCa. ProstaScint©, which has been successfully marketed, is a monoclonal antibody nuclide imaging agent targeting PSMA. It was approved for prostate cancer imaging by the US Food and Drug Administration (FDA) in the 1990s. However, binding sites of ProstaScint© and PSMA are located in the cell membrane and ProstaScint© mainly binds to the necrotic parts of the tumor rather than the viable tumor cells, therefore, ProstaScint© has not been promoted.
[0005] Recent studies have shown that a class of small-molecule compounds constructed based on glutamate-urea-glutamate (GUG) or glutamate-urea-lysine (GUL) exhibit high affinity for PSMA, which can be used in the diagnosis and treatment of prostate cancer with the help of various radionuclides. Some compounds such as6 8Ga-PSMA1,
18F-DCFPyL, 18F-FDCBC, 99mTc-MIP-1404, 99mTc-HYNIC-ALUG and the like are currently undergoing clinical experimental research. However, these compounds are all or partially excreted from the urinary system, which will affect the diagnosis of primary tumor of PCa and local recurrence of prostate after surgery.
SUMMARY OF THE PRESENT DISCLOSURE
[0006] The present invention provides new tissue-specific compounds for prostate cancer, and the use thereof in nuclear medicine as imaging agents and tracers for PCa. In particular, the present invention provides an imaging agent different from that of the prior art in terms of modification, wherein the imaging agent is not known or not recommended previously. The present invention avoids excretion of the imaging agent from urinary system, and tumor from being covered by high intake bladder.
[0007] The present invention relates to a compound of formula (1) or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein the formula (1) is: x
R R
0 N N
H1 H()
[0008] wherein: m is an integer from 1 to 5; n is an integer from 1 to 5; f and g each is 0 or 1; R and R' each is independently selected from H, and C-Cio alkyl; Q is -COOH, -SOOH, -SO3H, -SO4H, -POOH, -PO3H or -P04H2; X is an optionally substituted phenyl, naphthyl, biphenyl, indolyl, benzothiazolyl or quinolinyl, optionally substituted by at least one R group; Y is an optionally substituted aryl, an optionally substituted heterocyclic aryl, an optionally substituted cycloalkyl, or an optionally substituted heterocycloalkyl, optionally substituted by at least one R group, wherein the optionally substituted heterocycloalkyl is selected from N-piperidinyl or N-methylated piperidinium;
- H C
R'i AA1 is ,wherein Z= and R'=H, COOH, CH2COOH, C2H4COOH, CH(COOH)2, CH(CH2COOH)2, CH(COOH)(CH2COOH), CH2CH(COOH)2 or SO3H; i=1-3; and R=H or CH3.
[0009] Further, the formula (1) is a compound represented by formula (1-1):
PATENT Attorney Docket No.: PWWEP220040-MO
x
HCR R' HN--- II ~ 10 K ii( YH 2 I \I C--CtY'C NAA1
/ H~N H- in N ANH 2
Q N H H
[0010] Further, the R and R'each is independently selected from H and C-Cio alkyl;
the X is an optionally substituted phenyl, naphthyl, biphenyl, indolyl, benzothiazolyl or quinolinyl;
the optionally substituted heterocycloalkyl is selected from N-piperidinyl or N-methylated piperidinium.
[0011] The present invention further provides a radionuclide complex, which can be used in SPECT/CT imaging of a target tissue.
[0012] Specifically, the radionuclide complex comprises a radionuclide and a PSMA small molecule inhibitor, where the PSMA small molecule inhibitor has a structure represented by formula (11):
X H H HN-C-C-- C _ A 1 )-4-0~-t
_N"N 1TI
(II)
[0013] where Q, R, X, f, Y, g, m, R', AA1 and n are as defined above,
L is N-tris(hydroxymethyl)methylglycine, ethylenediamine-N,N'-diacetic acid, triphenylphosphine-3,3',3"-trisulfonic acid trisodium, disodium
PATENT Attorney Docket No.: PWWEP220040-MO
3,3'-(phenylphosphinediyl)bis(benzene-1-sulphonate), sodium diphenylphosphinobenzene-3-sulfonate, nicotinic acid, glucoheptonate, glucosamine, mannitol, or diphenylphosphinobenzoic acid.
[0014] Further, the complex is a compound represented by formula (II-1):
x
0 CH 2 R O R HN-C 1A4.1 NH4
OI L I 0 LT
Q N N Q H H
Formula (II-1)
[0015] Unless otherwise stated, the term "alkyl" itself or as part of another molecule in the present invention is a straight-chain or branched or cyclic hydrocarbyl group, or a combination thereof, which can be fully saturated, monounsaturated or polyunsaturated, and can include a bivalent and multivalent group. An "alkyl" residue is preferably C1 to C10 and may be unsubstituted or substituted (e.g., substituted with a halogen). A preferred alkyl residue is methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl or n-octyl or the like. This is also applicable to a corresponding cycloalkyl compound having 3 to 10 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like. An unsaturated alkyl is an alkyl group having one or more double bonds or triple bonds. Examples of the unsaturated alkyl includes, but are not limited to, vinyl, 2-propenyl, 2-butenyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- propynyl and 3-propynyl, 3-butynyl, and advanced homologs and isomers. Unless otherwise stated, the term "alkyl" is also used to include those derivatives of alkyl, such as "heteroalkyl", "haloalkyl" and "advanced alkyl".
[0016] As used herein, the term "aryl" refers to a closed ring structure, which has at least one ring having a conjugated -r-electron system and includes a carbocyclic aryl group and a heterocyclic aryl (or "heteroaryl" or "heteroaromatic") group. A carbocyclic group or a
PATENT Attorney Docket No.: PWWEP220040-MO
heterocyclic aromatic group may contain 5 to 20 ring atoms. The above term includes covalently linked monocyclic or condensed polycyclic (i.e., a ring that shares an adjacent pair of carbon atoms) group. The aromatic group can be unsubstituted or substituted. Non-limiting examples of "aromatic" or "aryl" groups include phenyl, 1-naphthyl, 2-naphthyl, 2-biphenylyl, 3-biphenylyl, 4-biphenylyl, anthryl and phenanthryl. The substituents for each of the above aryl and heteroaryl ring systems are selected from the acceptable substituents (e.g., alkyl, carbonyl, carboxyl, or halogen) described herein. When used together with other terms (including but not limited to aryloxy, arylthiooxy, and aralkyl), the term "aryl" includes aryl and heteroaryl ring. Thus, the term "aralkyl" or "alkaryl" is used to include those groups in which the aryl group is attached to the alkyl group (including but not limited to benzyl, phenethyl, pyridylmethyl, etc.), the alkyl group includes those whose carbon atoms (including but not limited to methylene) have been replaced by heteroatoms, or by oxygen atoms for illustration only. Examples of such aryl groups include, but are not limited to, phenoxymethyl, 2-pyridyloxymethyl, 3-(1-naphthyloxy)propyl, and the like.
[0017] "Heteroaryl" refers to an aryl group containing at least one heteroatom selected from N, 0, and S, wherein the nitrogen and sulfur atoms may be optionally oxidized, and the nitrogen atom may be optionally quaternized. The heteroaryl group can be substituted or unsubstituted. The heteroaryl group can be attached to the remaining part of a molecule through a heteroatom. Non-limiting examples of suitable groups include 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 4-benzothiazolyl, 5-benzothiazolyl, 6-benzothiazolyl, 7-benzothiazolyl, purinyl, 2-benzimidazolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7-indolyl, 1-isoquinolinyl, 5-isoquinolinyl, 2-quinoxalinyl, 5-quinoxalinyl, 2-quinolinyl, 3-quinolinyl, 4-quinolinyl, 5-quinolinyl, 6-quinolinyl, 7-quinolinyl or 8-quinolinyl.
[0018] The term "amino acid" refers to natural amino acids and unnatural amino acids, as well as amino acid analogs and amino acid mimetics that act in a manner similar to natural amino acids. Natural amino acids are the 20 common amino acids in their D- or L-forms
PATENT Attorney Docket No.: PWWEP220040-MO
(alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, praline, serine, threonine, tryptophan, tyrosine and valine) and pyrrolysine and selenocysteine. Amino acid analogs refer to compounds that have the same basic chemical structure as natural amino acids, for example, ex-carbon, which binds to hydrogen, carboxyl, amino and R groups. Such analogs can have modified R groups (for example, norleucine) or can have modified peptide backbones, while still remaining the same basic chemical structure as natural amino acids. Non-limiting examples of amino acid analogs include homoserine, norleucine, methionine sulfoxide and methionine methyl sulfonium. Amino acids may be referred to herein by their names, by their commonly known three-letter symbols, or by one-letter symbols (as recommended by the IUPAC-UB Biochemical Nomenclature Committee). "Unnatural amino acid" refers to an amino acid that is not one of the 20 common amino acids or pyrrolysine or selenocysteine. Other terms that may be used synonymously with the term "unnatural amino acid" are "non-naturally encoded amino acid", "non-natural amino acid", "non-naturally occurring amino acid", or "artificial amino acid". The term "unnatural amino acid" includes, but is not limited to, amino acids which are produced by modifying naturally encoded amino acids in their backbones or side chains. In some embodiments, the unnatural amino acid comprises carbonyl group, acetyl group, aminooxy group, hydrazine group, hydrazide group, semicarbazide group, azide group, or alkynyl group. In an embodiment, AA1 has the following chemical formula:
- H _ C
[0019] , wherein Z=
[0020] and R'= H, COOH, CH2COOH, C2H4COOH, CH(COOH)2, CH(CH2COOH)2, CH(COOH)(CH2COOH), CH2CH(COOH)2, or SO3H;
i=1-3; and R=H or CH3.
PATENT Attorney Docket No.: PWWEP220040-MO
[0021] In an embodiment, amino acids bring hydrophilic elements into the compounds of general formula I.
[0022] Some residues herein (including but not limited to unnatural amino acids) may exist in several tautomeric forms. All such tautomeric forms are considered as part of the compounds described herein. Additionally, all enol-keto forms of any compound herein are considered as part of the compositions described herein.
[0023] AA, i.e., a natural amino acid and/or non-naturally occurring amino acid, can be bound intramolecularly through a peptide or amide bond. However, in the case of an acidic amino acid (e.g., glutamic acid or aspartic acid), the binding site may alternatively be at the alpha-, beta- or gamma-position.
[0024] Although it is preferred that the Z group is -COOH, it can be easily replaced by biosteric substitutes such as -SO2H, -SO3H, -SO4H, -PO2H, -PO3H, -P04H2. See e.g. "The Practice of Medicinal Chemistry" (Academic Press New York, 1996), page 203.
[0025] Within the present invention, all residues are considered to be combinable unless otherwise stated in the definition of the residues. Conceivable subgroups of the residues are believed to be disclosed.
[0026] In the present invention, all chiral C atoms have the D- and/or L-configuration; furthermore, combinations within one compound are possible, i.e., some chiral C atoms may be in the D-configuration and the other chiral C atoms may be in the L-configuration.
[0027] The compound represented by formula (I) provided by the present invention can be selected from, but not limited to, the compounds having the following structures:
PATENT AttorneyDocket No.: PWWEP220040-MO
0 OH
O 0 H HO NN OHN 0 -~N NH
0 OH NH 2 NHH
NH O OH
0
H H 0 0
[0028] or OH H H N N HO OONH
HN 0 0
0 NH
0 OH
0 HO Y N'KN OH H H 0 0
[00291 or
PATENT Attorney Docket No.: PWWEP220040-MO
0 0 HN HN N NH NH 2 00 OH NH
0 NH 0 OH
0 HO N N OH H H 0 0
[0030] or O OH
0 0 H ON HNH N NH
0 OH NH 2 NH
0 OH
0 HO NNN O H H 0 0
[00311 or
PATENT Attorney Docket No.: PWWEP220040-MO
0 0 HN HN N NH
NH 2 0 OH NH
0 NH 0 OH
0 HO N N OH H H 0 0
[0032] or O OH
0 0 H HN O HNH
N NH
N OH NH 2 NH
O OH
0 HO N N OH H H 0 0
[00331 or
PATENT AttorneyDocket No.: PWWEP220040-MO
0 0 HN HN N NH O+N H NH 2 OH O NH
& aNH
O OH
0 HO NN OH H H O 0
[0034] or 0 0
HN HN N NH
O+N NH 2 OH 0 NH
0 NH 0 OH
0 HO N N OH H H 0 0
[0035] or
PATENT Attorney Docket No.: PWWEP220040-MO
0 OH
0 0 H HN N 0 N NH COOH 0 NH 2
NH OHH O NH O OH
0 HO N OH H H 0 0
[0036] or 0 0
HN HN N NH
COOH NH 2
NH
0 OH
0 HO N'JN OH H H 0 0
[00371 or
PATENT Attorney Docket No.: PWWEP220040-MO
OH H O NH2
NH
HN 0 0 O COOH NH
O NH O OH
0 HO NN OH H H 0 0
[0038] or 0 OH
O 0 H HN O HNH N
0N NH oy (' HO 0 NH 2
NH O NH O OH
0 HO N N OH H H 0 0
[00391 or
PATENT AttorneyDocket No.: PWWEP220040-MO
0 0 H HN
N NH HO 01 NH 2
NH O OH
0 HO N N OH H H 0 0
[0040] or 0 OH
0 0 H HN N HO 0 N N
H NH 0 HO N N OH
O H H O 0 0
[00411 or
PATENT AttorneyDocket No.: PWWEP220040-MO
0 OH
0 0 H
H O 0,1, HOOC H O O 0 N NNH
SNHNH 2
0 OH
0 HO N N OH H H 0 0
[0042] or 0 0 HN
0:OH
0 OH
0 HO N N OH H H 0 0
[0043] or
PATENT AttorneyDocket No.: PWWEP220040-MO
O OH H HOOC 0 N NH 2 H HO N N
O HH O 00 0 0 OO
0 HO JN OH H H O 0 O OH
[00441 or 0 OH
0 0 H N HN N
N NH 0[045 NH 2
NH
0 NH OO OHI OH
0 HO N'k OH H H 0 0
[0045] or
PATENT AttorneyDocket No.: PWWEP220040-MO
0 OH
0 0 H N HN O NH HO 0N 0 NH 2
NH O NH O OH
0 HO N N OH H H 0 0
[0046] or 0 OH
0 0 H N N N H H 0,,C HOOC 0 N N NH NH 2
0 NH OC HO 0 N NNO OH
[0047]OH 0 HO NJN OH H H 0 0
[0047] or
PATENT AttorneyDocket No.: PWWEP220040-MO
0 0 HN HN N NH COOH NH 2
aNH 0 NH O OH
0 HO N N OH H H O 0
[0048] or 0 0 HN N NH HO 01 NH 2
NH
0 OH
0 HO N)N OH H H 0 0
[0049] or
PATENT Attorney Docket No.: PWWEP220040-MO
0 0 HN
0HOOC N NH
H NH O OH 2 0 OH
0 NH 0 OH
0 HO N N OH H H 0 0
[0050] The complex of formula (II) provided by the present invention can be selected from, but not limited to, the complexes having the following structures:
0 OH
0 0 H HN N 0 N NH 0 N O OH 99m c1 NHI CCTc O OH L
(O NH O OH
0 HO N'N OH H H O
[ o
[00511 or
PATENT AttorneyDocket No.: PWWEP220040-MO
OH H O N -\ N NH 99mTc L HN 0 0
0 NH n OO O OH
0 HO N N OH H H 0 0
[0052] or 0 0 HN HN N NH
99MTc 0 OH NH O
0 OH
0 HO N'kN OH H H 0 0
[0053] or
PATENT AttorneyDocket No.: PWWEP220040-MO
O OH
O 0 H HO HNH NN
N NH
0 99 N OH mTc1 NH O L aoNH 0 OH
0 HO N N OH H H 0 0
[00541 or 0 0 HN HN N NH aII O OH 9M1
L aNH O NH O OH
0 HO N'KN OH H H 0 0
[0055] or
PATENT Attorney Docket No.: PWWEP220040-MO
O OH
O 0 H HN O HNH N NH O N N O OH NHm-jc
L O NH O OH
0 HO N N OH H H 0 0
[0056] or O OH
o O H HN N HNH
N NH o N N O99m NHI
O NH Y OH L O OH
0 HO N N OH H H 0 0
[00571or
PATENT AttorneyDocket No.: PWWEP220040-MO
0 0 HN HN N NH + N
0L
O NH O OH
[0058]OH ONHH I
0 HO OH H H 0 0
[0058] or 0 OH
0 0 H N HN N < H 0 N NH COOH 99 mTC
NHI L
ONH 0 OH
0 HO N)N OH H H 0 0
[0059] or
PATENT Attorney Docket No.: PWWEP220040-MO
0 0
HN N NH COOH N 99 0 m11
NH L O OH
0 HO OH H H 0 0
[0060] or
OH H o O N I 99 NH mTc L HN 0 0 O COOH NH
0 NH O OH
HO N N OH H H 0 0
[00611 or
PATENT Attorney Docket No.: PWWEP220040-MO
0 OH
0 0 H N HN N
S HO 0 N NH HN N
O OH NH Tc O0 L O NOH O OH
0 HO N OH H H O99m 1 0 0
[00621 or 0 0 HN HON Iak HN N NH -~HO 0 N I NH L
0 NH 0 OH
0 HO ' OH H H 0 0
[0063] or
PATENT Attorney Docket No.: PWWEP220040-MO
O OH
O 0 H HN N
HO NN NH 0 NH N
0 L HO N'N OH H H 0 0
[0064] or 0 OH 0 OH999 c O OH O 0 0 H N N NN HH O HOOC 0 N N 99 0 OH m 1
NH L O OH
0 HO N N OH H H 0 0
[00651 or 0 OH H HOOC 0 N" H H 1 N 99 N -- N M-I-c NI 0H 0L 0 H 0 0 OH
0 HO N)KN OH H H 0 0
[0066] or
PATENT Attorney Docket No.: PWWEP220040-MO
0 0 HN
OHO HOOC N NH N NH OHO HOH 99m O
0 NH L 0 OH
0 HO OH H H 0 0
[00671 or 0 OH
0 0 H HN N OH N NH 0"& COOHI H HN
NHr O0 L 0 NH 0 OH
0 HO, Nk OH H H 0 0
[0068] or
PATENT Attorney Docket No.: PWWEP220040-MO
0 OH
0 0 H N
HO 0 N NH I NH O 99 mc L
O NH O OH OO O 0 HO N N OH O O NH H H 0 0
[00691 or 0 OH
0 0 H N N N H H O, C: HOOC 0 N N
NH N 0 OH 9M1 99 Tc 0 NH L 0 OH
0 HO Y N'KN OH H H 0 0
[0070] or
PATENT AttorneyDocket No.: PWWEP220040-MO
0 0 HN HN N NH COOH N
com NHO L
O OH
0 HO NKN OH H H 0 0
[0071] or 0 0 HN--I lzl HN N NH HO 01
NH N L O OH
0 HO N'N OH H H 0 0
[00721 or
0 HN N H 0, HOC 00 N N NH N NH 9 I 0 OH 'Tc L (Izz)(DNH 0 OH
0 HO N'N OH H H 0 0
[0073] wherein:
[0074] L is N-tris(hydroxymethyl)methylglycine, ethylenediamine-N,N'-diacetic acid, triphenylphosphine-3,3',3"-trisulfonic acid trisodium, disodium 3,3' (phenylphosphinediyl)bis(benzene-1-sulphonate), sodium diphenylphosphinobenzene-3-sulfonate, nicotinic acid, glucoheptonate, glucosamine, mannitol, or diphenylphosphinobenzoic acid.
[0075] The above compound or complex provided by the present invention can be used in a method for imaging in a patient, in a method for diagnosing prostate cancer and/or its metastases, or in a method for treating prostate cancer and/or its metastases.
[0076] The present invention further provides a pharmaceutical composition comprising the aforementioned compound or complex, or pharmaceutically acceptable prodrug, salt or ester thereof, and pharmaceutically acceptable carrier. The pharmaceutical composition can be used in a method for imaging in a patient, in a method for diagnosing prostate cancer and/or its metastases, or in a method for treating prostate cancer and/or its metastases.
[0076A] The present invention further provides use of the above compound or complex or the pharmaceutically acceptable salt, prodrug or ester thereof in the preparation of a reagent for imaging in a patient.
[0076B] The present invention further provides use of the above compound or complex or the pharmaceutically acceptable salt, prodrug or ester thereof in the preparation of a reagent for diagnosing prostate cancer and/or its metastases
[0077] The 99mTc complex of general formula (II) of the present invention can be used for SPECT/CT imaging of prostate cancer and/or its metastases, and provides a new method for the diagnosis of prostate cancer. By modifying the intermediate linker of PSMA pharmacophoric group and radioactive coordination group, the lipophilicity of the
31A
PATENT Attorney Docket No.: PWWEP220040-MO
compound is adjusted, the ratio of the compound metabolized by liver and gallbladder is increased, and the excretion of the compound from urinary system is reduced, therefore, the adverse effect of physiological uptake on imaging results is avoided. Compared to other existing PSMA SPECT tracers, the compounds of the present invention, especially 99mTc-HYNIC-PSMA-XL-3, show excellent assessment of prostate cancer due to their low urinary clearance. Therefore, tracers in the present invention are suitable for the initial diagnosis of primary and recurrent prostate cancer.
BRIEF DESCRIPTION OF THE DRAWINGS
[0078] Fig. 1 shows an HPLC UV-vis spectrum of HYNIC-PSMA-XL-2.
[0079] Fig. 2 shows a mass spectrum of HYNIC-PSMA-XL-2.
[0080] Fig. 3 shows an HPLC UV spectrum of HYNIC-PSMA-XL-3.
[0081] Fig. 4 shows a mass spectrum of HYNIC-PSMA-XL-3.
[0082] Fig. 5 shows a Radio-HPLC spectrum of 99mTc-HYNIC/EDDA-PSMA-XL-2.
[0083] Fig. 6 shows a Radio-HPLC spectrum of 99mTc-HYNIC/EDDA-PSMA-XL-3.
[0084] Fig. 7 shows a Radio-HPLC spectrum of 99mTc-HYNIC/TPPTS-PSMA-XL-2.
[0085] Fig. 8 shows a Radio-HPLC spectrum of 99mTc-HYNIC/TPPTS-PSMA-XL-3.
[0086] Fig. 9 shows the stability of 99mTc-HYNIC/EDDA-PSMA-XL-2 and 99 mTc-HYNIC/EDDA-PSMA-XL-3 in vitro.
[0087] Fig. 10 shows an SPECT/CT image of 99mTc-HYNIC/EDDA-PSMA-XL-2 imaging under a LNCaP tumor model.
[0088] Fig. 11 shows an SPECT/CT image of 99mTc-HYNIC/EDDA-PSMA-XL-3 imaging under the LNCaP tumor model.
[0089] Fig. 12 shows an SPECT/CT image of 99mTc-HYNIC/EDDA-PSMA-XL-2 imaging under a PC-3 tumor model.
PATENT Attorney Docket No.: PWWEP220040-MO
[0090] Fig. 13 shows an SPECT/CT image of 99mTc-HYNIC/EDDA-PSMA-XL-3 imaging under the PC-3 tumor model.
[0091] Fig. 14 shows the in vivo distribution of 99mTc-HYNIC/EDDA-PSMA-XL-3 under the
LNCaP tumor model.
[0092] Fig. 15 shows a target-to-background ratio (TBR) image of different tissues undergoing SPECT/CT imaging after injection of 99mTc-HYNIC-PSMA-XL-3 into a prostate cancer patient.
[0093] Fig. 16 shows typical images of SPECT/CT imaging after injection of 99mTc-HYNIC-PSMA-XL-3 into a patient with primary prostate cancer.
[0094] Fig. 17 shows typical images of SPECT/CT imaging after injection of 99mTc-HYNIC-PSMA-XL-3 into a prostate cancer patient with multiple systemic metastases.
[0095] Fig. 18 shows pictures of 99mTc-HYNIC-PSMA-XL-3 SPECT/CT imaging tumors and corresponding immunohistochemical pictures of surgical specimens in a prostate cancer patient. The results show that the 99mTc-HYNIC-PSMA-XL-3 SPECT/CT imaging tumors in a prostate cancer patient were highly consistent with the immunohistochemical PSMA expression of the corresponding surgical specimens.
[0096] Fig. 19 shows primary tumors of a prostate cancer patient. The commonly used PSMA molecular probes 99mTc-HYNIC-ALUG and 68Ga-PSMA11 in clinic both have high physiological distributions in the bladder (A/B in Fig. 19), which affects the distinction between prostate tumors and bladder physiological regions. However, the 99mTc-HYNIC-PSMA-XL-3 of the present invention has a less distribution of radioactivity in the bladder (C in Figure 19), therefore, distinguishing prostate cancer tumors from normal tissue structures clearly is achieved, and laying the foundation for further clinical puncture, surgery and other applications.
PATENT Attorney Docket No.: PWWEP220040-MO
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0097] The following embodiments describe the present invention in detail, and these embodiments are provided for illustration only, they should not to be construed in any way as limitation of the present invention.
Embodiment 1
[0098] Synthesis of Glu-Urea-Lys-2Nal-AMB-Glu-Glu-HYNIC (HYNIC-PSMA-XL-2)
[0099] It was synthesized by solid-phase synthesis using 2 mmol of tert-butyl
ester-protected glutamic acid immobilized on 2-CTC resin as starting material, wherein 2 mol of N,N'-carbonyldiimidazole was added and then reacted at room temperature overnight. The unreacted N,N'-carbonyldiimidazole was eluted with DMF, methyl trifluoromethanesulfonate and triethylamine were added to react for 1 h, and then Fmoc-Lys(OtBu)-NH2 was added to react for 2 h. Then 1.96 mmol of HOBt and 2 mmol of DIC were used as amidation catalysts in DMF, followed by adding 2 mmol of Fmoc-2Nal-OH, Fmoc-4-aminomethyl-benzoic acid, Fmoc-Gu(OtBu)-OH, Fmoc-Glu(OtBu)-OH and Boc-HYNIC successively. Finally, the 2-CTC resin and the tert-butyl ester were removed with a mixture consisting of trifluoroacetic acid, triisopropylsilane and water (95/2.5/2.5) to obtain a crude product.
[00100] The obtained crude product was separated and purified by preparative RP-HPLC, and then the purified product was analyzed by analytical RP-HPLC and LC-MS. The HPLC spectrum was shown in Fig. 1, and the mass spectrum was shown in Fig. 2.
O CDI 0 0 MeOTi 0 20%piperidine
0 HN NH2 N N Q O 0 O H N N OFmoc-2-Na0
Fmoc-Lys(OtBe)-NH 2 0 0
HN H N NH N Fm 20%piperdine 20%pipeidine 20%piperidine 20%piperidie TFA 0 NH 0 NH
CC HN H H H FoNFmoc-N-CH-C-OH Fmoc-N-CH -OH Fno CH2 HO 0 NH H.
H OH OH
H N 0 Fmoc
Fmoc-4-(Aminomethyl)b-eziccd Fmoc-Gie(OtBu)-OH Fmoc-Glu(OtBu)-OH Fmoc-HYNIC H H 2-CTC HYNIC-PSMA-XL-2
PATENT Attorney Docket No.: PWWEP220040-MO
Synthetic reaction scheme of HYNIC-PSMA-XL-2
Embodiment 2
[00101] Synthesis of Glu-Urea-Lys-2Nal-AMB-Glu-HYNIC (HYNIC-PSMA-XL-3)
[00102]It was synthesized by solid-phase synthesis using 2 mmol of tert-butyl ester-protected glutamic acid immobilized on 2-CTC resin as starting material, wherein 2 mol of N,N'-carbonydiimidazole was added and then reacted at room temperature overnight. The unreacted N,N'-carbonyldiimidazole was eluted with DMF, methyl trifluoromethanesulfonate and triethylamine were added to react for 1 h, and then Fmoc-Lys(OtBu)-NH2 was added to react for 2 h. After that, 1.96 mmol of HOBt and 2 mmol of DIC were used as amidation catalysts in DMF, followed by adding 2 mmol of Fmoc-2Nal-OH, Fmoc-4-aminomethyl-benzoic acid, Fmoc-Glu(OtBu)-OH and Boc-HYNIC successively. Finally, the 2-CTC resin and the tert-butyl ester were removed with a mixture consisting of trifluoroacetic acid, triisopropylsilane and water (95/2.5/2.5) toobtain a crude product.
[00103] The obtained crude product was separated and purified by preparative RP-HPLC, and then the purified product was analyzed by analytical RP-HPLC and LC-MS. The HPLC spectrum was shown in Fig. 3, and the mass spectrum was shown in Fig. 4.
HN Fmoc O 0 CDI 0 0 Me OF o O 20%piperidine H HN-FoeN NH
NHNH N NN OH
N mHN -CH -- 2-NOH 0o 0F 0 0 Fo-Lyo(Ot)-NH 2 H HN
N NH H NH N N 20%pip~ddine 20%piper-idin~e 20%piperidhae TFA NH 0 OH
OHN 0o0 SFnmoe-N-CH-H OIO HO 0 NH "
oH CH2 NH
L~O N~ OOH C0NH * H H 0 Fmoc0 0 0 -<HOr NI OH
Fmnoc-4-(Aminomethyl)benoic acid Fmoc-Glu(OtBu)-OH Fmoc-HYNIC 0 H H 0
2-CTC HYNIC-PSMA-XL-3
Synthetic reaction scheme of HYNIC-PSMA-XL-3
PATENT Attorney Docket No.: PWWEP220040-MO
Embodiment 3
[00104] HYNIC-PSMA-XL-2 and HYNIC-PSMA-XL-3 affinity assay
[00105]The binding capacity of HYNIC-PSMA-XL-2 and HYNIC-PSMA-XL-3 to PSMA protein was determined by Surface Plasmon Resonance (SPR). Since the dissociations of HYNIC-PSMA-XL-2 and HYNIC-PSMA-XL-3 were both very slow with a kd beyond the detection limit of the instrument (1E-6), the final calculated KD of the binding of HYNIC-PSMA-XL-2 and PSMA protein should be less than 6.43 pM, and the calculated KD of the binding of HYNIC-PSMA-XL-3 and PSMA protein should be less than 4.857 pM based on the ka results. In order to compare with the reported PSMA inhibitors, the binding capacity of PSMA11, 19 F-PSMA1007, 2-PMPA and HYNIC-ALUG compounds publicly reported by our research group were determined by the same method. The specific KD values are listed in Table 1.
Table 1. Affinity KD values of different PSMA inhibitors to PSMA
Compound KD value (SPR method)
HYNIC-PSMA-XL-2 < 6.43 pM
HYNIC-PSMA-XL-3 < 4.897 pM
2-PMPA 9.868 nM
PSMA11 1.255 nM
19F-PSMA1007 64.92 nM
HYNIC-ALUG 299.4 nM
Embodiment 4
[00106] Preparation of 99mTc-HYNIC/EDDA-PSMA-XL-2 complex:
PATENT Attorney Docket No.: PWWEP220040-MO
[00107]1 pg of HYNIC-PSMA-XL-2, 5 mg of ethylenediamine-N,N'-diacetic acid, 50 mg of disodium succinate, 30 mg of succinic acid, 20 mg of Tricine, 100 mg of mannitol and 30 pg of stannous chloride were dissolved in 1 ml of sterile water for injection, then 0.5 ml of Na 99 mTcO4 eluent (1100 MBq) was added, after that the mixture was reacted in a boiling water bath for 20 min to obtain the target compound 99mTc-HYNIC/EDDA-PSMA-XL-2. The target compound has a radiochemical purity greater than 99% determined by Radio-HPLC. The relevant analytical spectrum was shown in Fig. 5.
0 OH 0 OH
0 0 0 0 H H N N N HN H 0 H HN N 0~ N NH2 0 N NH 0 OH NH2 0 OH 0 N O H EDDA, Tricine NH O
NH HN CI NH NH Na9smTcO4,SnCI 0 OH 10min, 1000C OH
HO N N OH HO N N OH H H H H 0 0 0 0 HYNIC-PSMA-XL-2 99-Tc-HYNIC/EDDA-PSMA-XL-2
Synthetic reaction scheme of 99mTc-HYNIC/EDDA-PSMA-XL-2
Embodiment 5
[001081Preparation of 99mTc-HYNIC/EDDA-PSMA-XL-3 complex:
[00109]10 pg of HYNIC-PSMA-XL-3, 50 mg of ethylenediamine-N,N'-diacetic acid, 20 mg of disodium succinate, 10 mg of succinic acid, 1 mg of Tricine, 40 mg of mannitol and 500 pg of stannous chloride were dissolved in 0.5 ml of sterile water for injection, then 2 ml of Na 99 mTcO4 eluent (1100 MBq) was added, after that the mixture was reacted in a boiling water bath for 20 min to obtain the target compound 99mTc-HYNIC/EDDA-PSMA-XL-3. The target compound has a radiochemical purity greater than 99% determined by Radio-HPLC. The relevant analytical spectrum was shown in Fig. 6.
PATENT Attorney Docket No.: PWWEP220040-MO
0 0 0 0 HN 'HN HN HN HN N NH N NH NH 2 N H O Os O O HH EDDA, Tricine NamTcO 4 , SnC1 2 HN C1 H 0i~r NH 10mn, 100*C 0 N H H
0 H H
0 O
HO N KN OH HO N N H H H O O H H 0 0 0 0 HYNIC-PSMA-XL-3 9mTc-HYNIC/EDDA-PSMA-XL-3
Synthetic reaction scheme of 99mTc-HYNIC/EDDA-PSMA-XL-3
Embodiment 6
[00110] Preparation of 99mTc-HYNIC/TPPTS-PSMA-XL-2 complex
[00111]50 pg of HYNIC-PSMA-XL-2, 1 mg of triphenylphosphine-3,3',3"-trisulfonic acid trisodium, 35 mg of disodium succinate, 5 mg of succinic acid, 15 mg of Tricine and 10 pg of stannous chloride were dissolved in 0.8 ml of sterile water for injection, then 1 ml of Na 99mTcO4 eluent (1100 MBq) was added, after taht the mixture was reacted in a boiling water bath for 20 min to obtain the target compound 99mTc-HYNIC/TPPMS-PSMA-XL-2. The target compound has a radiochemical purity greater than 99% determined by Radio-HPLC. The relevant analytical spectrum was shown in Fig. 7.
O OH 0 OH
O O TPPTS, Tricine O O H H N Na9TCO 1 N N80 3S HN N Nam O HN N N S H 2 20min,100°H H H N N NH NN NH S 3Na 0 OH N 0 HN NN ONS' 2 O
NH ~)~LNH HICN 0 \Tl SO 3Na
0 OH 0 OH OH HH 0 0 HO, ' OH HO N OH H H H H 0 0 0 0 99 HYNIC-PSMA-XL-2 -Tc-H[YNIC/TPPTS-PSMA-XL-2
Synthetic reaction scheme of 99mTc-HYNIC/TPPTS-PSMA-XL-2
Embodiment 7
PATENT Attorney Docket No.: PWWEP220040-MO
[00112] Preparation of the 99mTc-HYNIC/TPPTS-PSMA-XL-3 complex
[00113]100 pg of HYNIC-PSMA-XL-3, 25 mg of Triphenylphosphine-3,3',3"-trisulfonic acid trisodium, 45 mg of disodium succinate, 20 mg of succinic acid, 50 mg of Tricine and 60 mg of mannitol were dissolved in 2 ml of sterile water for injection, then 1 ml of Na9 9mTcO 4
eluent (1100 MBq) was added, after that the mixture was reacted in a boiling water bath for 20 min to obtain the target compound 99mTc-HYNIC/TPPMS-PSMA-XL-3. The target compound has a radiochemical purity greater than 99% determined by Radio-HPLC. The relevant analytical spectrum was shown in Fig. 8.
0 0 0 0 S HNN HN HN NaO3 HN HN N NH N NH SO 3 Na
NH 2 N H 0 H O O NH TPPTS, Tricine NH H\ S
NH~ Na'cO- N0 SO3Na ~ONH 10min, 100°C 0HNH O 0 OH 0 H OH H
0 0 HO N N OH HO N N H H H H H 0 0 0 0 HYNIC-PSMA-XL-3 9mTc-HYNC/TPPTS-PSMA-XL-3
Synthetic reaction scheme of 99mTc-HYNIC/TPPTS-PSMA-XL-3
Embodiment 8
[00114]In vitro stability experiments of the complexes:
A certain amount of 99mTc-HYNIC/EDDA-PSMA-XL-2 and 99mTc-HYNIC/EDDA-PSMA-XL-3 were added to PBS and fresh mouse serum respectively, and the radiochemical purity was determined at different time points to detect the stability of the two complexes. The results were shown in Fig. 9, the two complexes both have radiochemical purity greater than 90% and maintain high stability after 6 h.
Embodiment 9
[00115] Cell uptake experiments:
PATENT Attorney Docket No.: PWWEP220040-MO
[00116] Human prostate cancer LNCaP cells (PSMA positive) were cultured in a RPMI 1640 medium containing 10% fetal bovine serum and 1% penicillin-streptomycin double antibody under 37 0C with 5% C02 and saturated humidity in the incubator. When the cells reach log phase, they were digested with 0.25% trypsin, then the cells were collected and washed twice with PBS, after that a cell suspension was obtained for further culture. A fixed number of cell lines (1.0x106 cells/1ml) was placed in each well of a 24-well cell culture dish, and the experiment was performed after the logarithmic growth phase.
[00117]The cells were divided into an experimental group and a blocking group. 0.5 pCi of the complex 99mTc-HYNIC/EDDA-PSMA-XL-2 or 99mTc-HYNIC/EDDA-PSMA-XL-3 was added to each well, wherein an excess of PSMA inhibitor 2-PMPA (1000-fold molar equivalent) was added to the blocking group half an hour in advance. 6 groups of experiments were carried out in parallel. After 1 h, the culture medium was aspirated, placed in a y-counting tube, and then washed three times with PBS. The washing solution and the culture medium were combined for storage. Then the cells were trypsinized, collected in another counting tube, and the percentage of cell uptake was calculated by a y-counting tube. The results were shown in Table 2:
Table 2. Results of LNCaP cell uptake experiments
Compound Experimental group Blocking group
HYNIX-PSMA-XL-2 16.54 ±1.33% 3.07 0.80%
HYNIX-PSMA-XL-3 14.01 ±1.11% 2. 66 0.51%
[00118] The results show that both 99mTc-HYNIX-PSMA-XL-2 and 99mTc-HYNIX-PSMA-XL-3 could highly specifically bind to PSMA-positive LNCaP cells.
Embodiment 10
PATENT Attorney Docket No.: PWWEP220040-MO
[00119] SPECT imaging studies:
[00120]Male SCID mice weighing 18-20 g, were provided by SHANGHAI SLAC LABORATORY ANIMAL CO. LTD, and were raised in the SPF class animal laboratory of the Laboratory Animal Department of Fudan University. After two days of adaptive feeding in the animal room, LNCaP human prostate cancer cells were injected subcutaneously into the armpit of nude mice with an injection volume of 0.2 ml (1x10 7 cells/ml dispersed in % Matrigel). The feeding was continued for 4-6 weeks after injection, and the mice were used for imaging experiments when their solid tumor mass grows to 500-600 mm 3
.
[00121]1mCi/0.2 ml of the 99mTc-HYNIC/EDDA-PSMA-XL-2 or 99mTc-HYNIC/EDDA-PSMA-XL-3 complex was injected into tail vein of the tumor-bearing mice. 2 hours after injection, the experimental animals were imaged with Small-Animal SPECT/CT. The images were shown in Figs. 10 and 11.
[00122]Male Balb/c nude mice weighing 18-20 g, were provided by SHANGHAI SLAC LABORATORY ANIMAL CO. LTD, and were raised in the SPF class animal laboratory of the Laboratory Animal Department of Fudan University. After two days of adaptive feeding in the animal room, PC-3 human prostate cancer cells were injected subcutaneously into the armpit of nude mice with an injection volume of 0.2 ml. The feeding was continued for 4-6 weeks after injection, and the mice were used for imaging experiments when the solid tumor mass grows to 500-600 mm 3 .
[00123]1mCi/0.2 ml of the 99mTc-HYNIC/EDDA-PSMA-XL-2 or 99mTc-HYNIC/EDDA-PSMA-XL-3 complex was injected into tail vein of the tumor-bearing mice. 2 hours after injection, the experimental animals were imaged with Small-Animal SPECT/CT. The images were shown in Figs. 12 and 13.
Embodiment 11
[00124]In vivo distribution study in mice under the prostate tumor model
[00125]Male SCID mice weighing 18-20 g, were provided by SHANGHAI SLAC LABORATORY ANIMAL CO. LTD, and were raised in the SPF class animal laboratory of
PATENT Attorney Docket No.: PWWEP220040-MO
the Laboratory Animal Department of Fudan University. After two days of adaptive feeding in the animal room, LNCaP human prostate cancer cells were injected subcutaneously into the armpit of nude mice with an injection volume of 0.2 ml (1x107 cells/ml dispersed in a % Matrigel). The feeding was continued for 4-6 weeks after injection, and the mice were used for in vivo distribution experiments when the solid tumor mass grows to 500-600 mm 3
[00126]20 pCi/0.2 ml of the 99mTc-HYNIC/EDDA-PSMA-XL-3 complex was injected into tail vein of tumor-bearing mice. 0.5, 1 and 2 hours after injection, the mice were sacrificed under anesthesia and dissected. Each organ tissue was weighed, and the radioactivity was measured to calculate the drug uptake of each tissue. The results were shown in Fig. 14.
Embodiment 12
[00127] Preparation of 99mTc-HYNIC-PSMA-XL-3 lyophilized kit:
[00128]1 mg of HYNIX-PSMA-XL-3, 1 g of disodium succinate, 0.3 g of succinic acid, 1 g of Tricine, 0.5 g of EDDA and 10 mg of SnCl2 were dissolve in sterile water for injection, and metered to 100 ml. The mixture solution was sterilized by a sterile Millipore filter for subsequent packaging.
[00129]1 mlof the above solution was taken and placed in a 10 ml of sterile vial for split charging into 100 vials, then lyophilized in nitrogen atmosphere, and finally sealed for preservation.
[00130]Lyophilized kits were randomly selected and tested the sterility and bacterial endotoxin.
Embodiment 13
[00131] 99mTc-HYNIC-PSMA-XL-3 for human use
[00132]30-100 mCi of Na 99mTcO4 solution was added to a vial of 99mTc-HYNIC-PSMA-XL-3
lyophilized kit, and reacted at 100 0 C for 10 min. The radiochemical purity of
PATENT Attorney Docket No.: PWWEP220040-MO
99mTc-HYNIX-PSMA-XL-3 was determined by radio-TLC. Radionuclide purity was controlled by half-life measurements as well as gamma spectroscopy. The pH, clarity, radioactive concentration, as well as sterility and bacterial endotoxin of product solution were tested.
Embodiment 14
[00133]Application of 99mTc-HYNIX-PSMA-XL-3 in patients with prostate cancer.
[00134]SPECT/CT imaging was performed on 10 patients with prostate cancer, including 5 patients with primary prostate cancer, 3 patients with biochemical recurrence, and 2 patients with hormone-resistant prostate cancer. The specific clinical information was shown in Table 3. The patients were injected with about 740MBq of 99mTc-HYNIC-PSMA-XL-3, and 2 hours later, they were examined by a Discovery 670 (GE, USA) scanner. Taking the right obturator internus muscle as the background, the target-to-background ratio (TBR) was calculated, and the results were shown in Fig. 15. It can be seen that the distribution of radioactivity in the bladder is low, which is significantly lower than the tumor uptake, indicating excellent diagnostic performance for the primary tumors. A typical example was shown in Fig. 16. In addition, the tumor targeting is high and has a superior detection value for metastases such as lymph nodes/bone. A typical example was shown in Fig. 17.
Table 3. Clinical characteristics of 10 patients with prostate cancer
No.Age Pathology of primary Gleason State PSA value Tumor location tumors Score before imaging (ng/ml)
1 77 acinar 5+4 before 9.9 prostate adenocarcinoma treatment (puncture)
4 56 acinar 4+3 before 15.23 prostate adenocarcinoma treatment
PATENT Attorney Docket No.: PWWEP220040-MO
(puncture)
71 ductal 4+3 before 27.82 prostate + pelvic treatment lymph nodes adenocarcinoma (puncture)
6 68 acinar 4+4 before 18.22 prostate + pelvic adenocarcinoma treatment lymph nodes (puncture)
2 62 acinar 3+4 before 34.8 prostate
+ adenocarcinoma treatment multiple lymph (puncture) nodes+ bone
3 80 acinar 5+4 biochemical 0.78 T12+L5 vertebral adenocarcinoma recurrence body (radical surgery)
7 72 acinar 4+5 biochemical 1.22 prostatic fossa adenocarcinoma recurrence (radical surgery)
8 69 acinar 4+4 biochemical 7.78 right iliac blood adenocarcinoma recurrence vessels (radical surgery)
9 59 acinar 4+5 hormone 34.91 multiple bones adenocarcinoma resistance (radical surgery) period
70 ductal 5+5 hormone 12.56 lymph node +
resistance bone adenocarcinoma period (puncture)
[00135]Four of the five patients with primary prostate cancer underwent radical prostatectomy, and one of the three patients with biochemical recurrence prostate cancer
PATENT Attorney Docket No.: PWWEP220040-MO
underwent salvage lymph node dissection. Without knowing the results of 99mTc-HYNIC-PSMA-XL-3 SPECT/CT, pathology specialists performed pathological analysis of samples. Representative sections were stained by immunohistochemistry method, deparaffinized in xylene and rehydrated in graded ethanol series. Antigen retrieval was performed with the aid of autoclave and retrieval buffer (Target Retrieval Solution, Dako). Mouse monoclonal antibody against PSMA (clone 3E6, Dako) was diluted at a 1:100 dilution and incubated overnight at 40 C, followed by immunodetection using the Histostain-Plus Detection Kit (Invitrogen). Stained sections were scanned using Nanozoomer 2.0-HT Scansystem (Hamamatsu Photonics) to generate digital overall images. Pathological PSMA expression was consistent with high uptake tumors in SPECT/CT, and a typical case was shown in Fig. 18.
Embodiment 15
[00136] Comparative study of 99mTc-HYNIC-PSMA-XL-3 and existing PSMA imaging agents that commonly used in clinic
[00137]15 patients with prostate cancer were randomly divided into 3 groups. One group underwent 99mTc-HYNIC-ALUG SPECT/CT, one group underwent 68Ga-PSMA11 PET/CT, and one group underwent 99mTc-HYNIC-PSMA-XL3 SPECT/CT. The results showed that the bladders imaged by 99mTc-HYNIC-ALUG SPECT/CT and 68Ga-PSMA11 PET/CT both exhibited a higher radiophysiological distribution (as shown in A and B of Fig. 19), which affected the distinction between prostate tumors and bladder physiological regions. In contrast, the bladders imaged by 99mTc-HYNIC-PSMA-XL3 SPECT/CT exhibited a very low distribution of radioactivity (as shown in C of Fig. 19), which can clearly distinguish prostate tumors from normal tissue structures, laying the foundation for further clinical puncture, surgery and other applications.
Embodiment 16
[00138] Comparison of 99mTc-HYNIC-PSMA-XL-3 SPECT/CT and 68Ga-PSMA11 PET/CT
PATENT Attorney Docket No.: PWWEP220040-MO
[00139]10 patients with biochemical recurrent prostate cancer were randomly divided into two groups. The basic clinical information of the two groups was similar: they both have previously received radical prostatectomy, and the current PSA of them were 1-3 ng/ml, and the GS score of them were 8-9. One group underwent 68Ga-PSMA11 PET/CT, and the other group underwent 99mTc-PSMA-XL SPECT/CT.
Table 4. Clinical characteristics and examination methods of 10 patients with prostate cancer
No. PSA GS Examination method Number of With or without tumors local recurrence
1 1.2 8 68Ga-PSMA11 2 no
2 2.2 8 68Ga-PSMA11 1 no
3 2.5 9 68Ga-PSMA11 4 yes
4 0.8 8 68Ga-PSMA11 0 no
5 1.7 9 68Ga-PSMA11 1 no
6 2.4 9 99mTc-PSMA-XL 3 yes
7 0.6 8 99mTc-PSMA-XL 1 no
8 2.1 8 99mTc-PSMA-XL 2 no
9 1.6 8 99mTc-PSMA-XL 0 no
10 0.7 9 99mTc-PSMA-XL 4 no
[0014o]After the preliminary statistics of the 10 patients, the positive rates of 68Ga-PSMA11
and 99mTc-PSMA-XL imaging were both 80%, and at the same time, 1 patient in both 68Ga-PSMA11 and 99mTc-PSMA-XL imaging were found to have local recurrence in the
prostatic fossa. 99mTc-PSMA-XL imaging is not inferior to 68Ga-PSMA11 imaging, which will be supported by designating prospective randomized controlled clinical trials and expanding the sample size in the future.
PATENT Attorney Docket No.: PWWEP220040-MO
[00141] The meanings of the English abbreviations herein were shown in Table 5:
English Chinese full names English full names abbreviations
Glu @ggR Glutamic acid
Lys 0g Lysine
2Nal 2-A -3 -W 2-amino-3-(naphthalen-2-yl)propanoic acid
AMB 4-A M r|-Tg994-aminobenzoic acid
HYNIC 6-S$V fI9 6-HYDRAZINONICOTINIC ACID
PSMA RigWJt TA Rc Prostate Specific Membrane Antigen
EDDA jJ-N,N'-izgg Ethylenediamine-N,N'-diacetic acid
TPPTS Hgff]ftfj Triphenylphosphine-3,3',3"-trisulfonic acid trisodium
2-PMPA 2-(Phosphonomethyl)pentanedioic acid
PSMA11 They are all PSMA inhibitors synthesized based on 19 F-PSMA1007 Glu-Urea-Lys structure
HYNIC-ALUG
[00142] Embodiments of the present invention are described herein, comprising the preferred mode of the present invention known to the inventors. After reading the foregoing description, variations of those embodiments may become apparent to those skilled in the art. The inventors expect that those skilled in the art can suitably utilize such variations, and the present invention can be implemented differently from that described herein. Thus, as permitted by law, the present invention includes all variations and equivalents of the subject matter described in the claims. Moreover, unless otherwise indicated herein or otherwise obviously contradictory to the context, the elements described above in any combination of all possible modifications are included in the present invention.
[00143] Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
[00144] The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

Claims (15)

The claims defining the invention are as follows:
1. A compound of formula (1) or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein the formula (1) is:
R F7 0R I ---- N C YNAO R RH
0 N N
H1 H()
wherein: m is an integer from 1 to 5; n is an integer from 1 to 5; f and g each is 0 or 1; R and R' each is independently selected from H, and C-Cio alkyl; Q is -COOH, -SOOH, -SO3H, -SO4H, -POOH, -PO3H or -P04H2; X is an optionally substituted phenyl, naphthyl, biphenyl, indolyl, benzothiazolyl or quinolinyl, optionally substituted by at least one R group; Y is an optionally substituted aryl, an optionally substituted heterocyclic aryl, an optionally substituted cycloalkyl, or an optionally substituted heterocycloalkyl, optionally substituted by at least one R group, wherein the optionally substituted heterocycloalkyl is selected from N-piperidinyl or N-methylated piperidinium;
- H C RR
AA1 is ,wherein Z= and R'=H, COOH, CH2COOH, C2H4COOH, CH(COOH)2, CH(CH2COOH)2, CH(COOH)(CH2COOH), CH2CH(COOH)2 or SO3H; i=1-3; and R=H or CH3.
2. The compound of formula (1) or the pharmaceutically acceptable salt, prodrug or ester thereof according to claim 1, wherein the formula (1) is a compound represented by formula (1-1): x oR' %fH2)fH2 ~-N NH2
H0H (1-1
HI H
3. The compound according to claim 1 or 2, having the following structures:
0 OH
0 0 H N HN N
N NH
0 OH NH 2 NH O OH 0 NH O OH
0 HO NN OH H H 0 0
or
OH H
NH HN N O 0
ONH NH HOO N OH OH O NH0 O OH
0 HO N N OH O H H 0 0
or
0 0 HN HN N NH NH 2 00 OH NH
N0 NH
0 OH
0 HO 0OH H H 0 0
or
0 OH
0 0 H HN N H 0 N NH 0 0O OH NH 2
aNH O NH 0 OH
0 HO N N OH H H 0 0
or 0
H HN I N.z
N NH 0 NH 2 0 OH NH
N.0~ NH 0 OH
0 HO N"KN OH H H 0 0
or
0 OH
0 0 H HN N H 0 N NH O NO NH2 y0 OHNH
aNH O NH
O OH
0 HO N N OH H H 0 0
or 0 0 HN HN)
N NH
NNH
N.0 NH 0 OH
0 HO Y N'JN OH H H 0 0
or
0 HN O HN N NH NH 2 0 N 0 OH NH
O NH O OH
0 HO N",N OH H H 0 0
or
0 OH
0 0 H N HN N
N NH COOH 0 NH 2
aNH O NH 0 OH
0 HO N' NZ OH H H 0 0
or
0
HN HN
N NH COOH NH 2
NH
O NH 0 OH
0 HO N0N OH H H 0 0
or
OH H O o NH 0 NH2 NOH
HN O O 5H 0
rCOOH O OH
0 N NH 0 OH
0 HO J,'~ OH YH H 0 0
or
0 OH
0 0 H HN N H HO 0 N NH 0 NH 2
NH
O NH 0 OH
0 HO N)N OH H H 0 0
or
0 0
HN HN-a
N NH HO 01 NH 2
NH
co NH 0 OH
0 1 HO N N OH H H 0 0
or
0 OH
0 0
O O 00 HO0OH NH2
HO NNN OH 0 H 0 H
or
0 OH
0 0
OH
N H
N N
0 0 H
H H
or
0 HN
0, z HOOC N NH
NH NH 2 0 OH ONH O OH
0 HO NkN OH H H 0 0
or
O OH H HOOC 0 5 N NH2 H H NN Nyf:N
0 H0 HOON O NH O OH OH O O 0 HO N N OH H H O 0 0
or
O OH
H 0 H N HN N O OH N NH COOH
ONH
O NH O OH
0 HO N)N OH H H 0 0
or
5 OH
0 0 H N HN N H HO 0 N NH NH 2 Olz~r NH
0 NH O OH
0 HO NKOH H H 0 0
or
O OH
O 0
OH NHH N NH
0 OH NH2
O H O OOHOH
0 HO NN OH H H 0 0
or 0 0 HN N NH
0COOH NH 2
NH
0 NH 0 OH
0 HO N0 OH H H 0 0
or
0 HN HN-K N NH HO 01 NH 2
NH
O NH 0 OH
0 HO N N OH H H 0 0
or 0 0 HN N H 0,,) HOOC N NH H NH 0 OH
0 NH 0 OH
0 HO N N OH H H 0 0
4. A 99mTc complex of the compound of formula (I) according to claim 1, having a structure of formula (II):
X
H RR R R 0 H N1 ---- -Y-N AA,)- R RI
f L O N N H H Formula (II)
wherein Q, R, X, f, Y, g, m, R', AA1 and n are as defined in claim 1, and L is N-tris(hydroxymethyl)methylglycine, ethylenediamine-N,N'-diacetic acid, triphenylphosphine-3,3',3"-trisulfonic acid trisodium, disodium 3,3' (phenylphosphinediyl) bis(benzene-1-sulphonate), sodium diphenylphosphinobenzene-3-sulfonate,nicotinicacid,glucoheptonate,glucosamine, mannitol, or diphenylphosphinobenzoic acid;
5. The complex according to claim 4, wherein the complex is a compound represented by formula (11-1): X
0 CH 2 R 0 R' O II I H2 H 1 ~i HN- - N C C Y - -NAA21 NH
-mN N 99 Q mTc
0L
0 N ~N Q H H(1-).
6. The complex according to claim 4 or 5, wherein the complex is selected from the following compounds
O OH
0 o H N HN N HH O N NH H N O OH 99 Tc NHI N L
0 NH O OH
0 HO N OH H H 0 0
or OH H 0 0 N\
NH 99m-j
L HN O N 0
NH OH 0 NH 0 0 OH
0 HO Y~ OH H H 0 0
or
0 HN HN N NH N
S 0 OH 99 mTc NH L
0 OH
0 HO N N OH O H H 0 0
or
0 OH
0 0 H HN NNH H
N NH 0 99 N O OH MTC11
O0 L
0 OH O H I 0 HO NN OH I H H 0 0
or
0 HN HN N NH N 0 4Ir 01 99 O OH mTc NH L
0 NH 0 OH
0 HO NKOH H H 0 0
or 0 OH
0 0 H HN N H N NH 0 N N NH OH
L aNH 0 OH
0 HO NN OH I' H H 0 0
or
0 OH
0 0 H HN N H 0 N NH 0 NN 0 OH 99 mTc or" NHI L ''0 NH
O OH
0 HO N OH H H 0 0
or 0 0 HN N HN N NH N 0 N 99 "N0 OH MT11
'N O NH
0 OH
0 HO N OH YH H 0 0
or
0 OH
0 0 H N HN N
N NH OOOH H NN co NHI 0 ' L
0 OH
0 HO N OH COOH99 H H c1 0 0
or 0 0 HN HN N NH COOH N 99 0 mTc
NN NH L
0 NH 0 OH
0 HO Y~ OH H H 0 0
or
OH Z:- H 0 0 N\N N I L HN O 0
COOH NH
0 NH O OH
0 HO NN OH H H O 0
or 0 OH
0 0 H N HN N H 0C - ~HO 0N NH 0 N 99MT11
L N. -~-0 NH
0 OH
0 HO NN OH H H 0 0
or
0
HNN
N NH HO 0 N I OH L
NH N0 HO 0 N. OHm 0 OH
0 HO NK N OH H H 0 0
or 0 OH
0 0
HN N"a H 0 HO 0 N NH N
0 L HO0 N' N OH H H 0 0
or
0 OH
O 0 H N ~N N H H O -O "HOOC 0 N N N IN NH 99 N 0 OH MTC11
NH "-a L O OH
0 HO N'JN OH H H 0 0
or O OH H HOOC 0 N HH 1i N Nyl N 99 mTc NI 0H 0L O NH O 0 OH
0 HO N H H OH
0 0
or 0 0
HN 0 HOOC N NH N NHN 0 OH 99 mTc
0 NHL O OH
0 HO NJN OH YH H 0 0 or 0 OH
0 0 H N OOKO HN N 0 H N NH COOH N
99 mTC NH L
NH O OH
0 HO N N OH H H 0 0
or O OH
H 0 H N HN N H HO 0 N NH I NH 9 TI O0 L
0 NH O OH
0 HO NN OH H H 0 0
or
0 OH
0 0 H N
' N NH
NH N O OH 9M1 99 Tc a',~NH L
O OH
0 HO Y~ OH H H 0 0
or 0 0 HN HN N NH COOH N 99 mTc "",NH L
""N 0 NH 0 OH
0 HO NN OH H H 0 0
or
0 HN HN HNK N NH HO I 0 N O 99 || mTc NH L
0 NH 0 OH
0 HO N N OH O H H 0 0
or 0 0 HN N H 0HHOOC N NH N NH I OH HmTc L (': ):DNH 0 OH
0 HO, NKN OH H H 0 0
7. A preparation method of the complex according to any one of claims 4-6, comprising formulating 0.5-2 ml of a mixture containing 1-100 pg of the compound according to any one of claims 1 and 2, 0-500 pg of stannous chloride, 1- 50 mg of a ligand L, -50 mg of disodium succinate, 5-30 mg of succinic acid, and 0-100 mg of mannitol in a 10-mL vial; adding 0.5-2 mL of Na 99mTcO4 solution (10-100 mCi); heating the vial in a 100°C water bath to carry out reaction for 10-20 minutes; and cooling at room temperature for 10 minutes after the reaction is completed; thus obtaining the compound according to any one of claims 5-8; wherein the ligand L is selected from N-tris(hydroxymethyl)methylglycine, ethylenediaminediacetic acid, triphenylphosphine-3,3',3"-trisulfonate, disodium 3,3' (phenylphosphinediyl)bis(benzene-1-sulphonate), sodium diphenylphosphinobenzene-3-sulfonate, nicotinic acid, glucoheptonate, glucosamine, mannitol, or diphenylphosphinobenzoic acid.
8. A pharmaceutical composition comprising the compound or the complex according to any one of claims 1 to 6, or the pharmaceutically acceptable salt, prodrug or ester thereof, and a pharmaceutically acceptable carrier.
9. Use of the compound or complex according to any one of claims 1 to 6 or the pharmaceutically acceptable salt, prodrug or ester thereof in the preparation of a reagent for imaging in a patient.
10. Use of the compound or complex according to any one of claims 1 to 6 or the pharmaceutically acceptable salt, prodrug or ester thereof in the preparation of a reagent for diagnosing prostate cancer and/or its metastases.
11. Use of the pharmaceutical composition according to claim 8 in the preparation of a reagent for imaging in a patient.
12. Use of the pharmaceutical composition according to claim 8 in the preparation of a reagent for diagnosing prostate cancer and/or its metastases.
13. A method of imaging in a patient, comprising injecting said patient with the pharmaceutical composition according to claim 8.
14. A method of diagnosing prostate cancer and/or its metastases in a patient, comprising injecting said patient with the pharmaceutical composition according to claim 8.
15. A complex prepared by the method of claim 7.
AU2021229984A 2020-03-03 2021-04-13 PSMA combiner and use thereof Active AU2021229984B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010140466.7A CN111253465A (en) 2020-03-03 2020-03-03 PSMA binding agent and application thereof
CN202010140466.7 2020-03-03
PCT/CN2021/086783 WO2021175338A1 (en) 2020-03-03 2021-04-13 Psma combiner and use thereof

Publications (2)

Publication Number Publication Date
AU2021229984A1 AU2021229984A1 (en) 2022-10-27
AU2021229984B2 true AU2021229984B2 (en) 2024-04-04

Family

ID=70944493

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021229984A Active AU2021229984B2 (en) 2020-03-03 2021-04-13 PSMA combiner and use thereof

Country Status (6)

Country Link
US (1) US20220315507A1 (en)
EP (1) EP4011903A4 (en)
CN (3) CN111253465A (en)
AU (1) AU2021229984B2 (en)
CA (1) CA3179523A1 (en)
WO (1) WO2021175338A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111253465A (en) * 2020-03-03 2020-06-09 复旦大学附属肿瘤医院 PSMA binding agent and application thereof
AU2022216463A1 (en) * 2021-02-08 2023-08-17 Stichting Radboud Universitair Medisch Centrum Psma-targeting ligands for multimodal applications
WO2023030434A1 (en) * 2021-09-01 2023-03-09 天津恒瑞医药有限公司 Inhibitor of prostate specific membrane antigen and pharmaceutical use thereof
WO2023030509A1 (en) * 2021-09-03 2023-03-09 晶核生物医药科技(南京)有限公司 Peptide-urea derivative, pharmaceutical composition containing same and application thereof
CN115260155B (en) * 2022-08-08 2023-11-10 北京师范大学 Glutamic acid-urea derivative containing triazole ring and hydrazinonigulamido and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018005899A2 (en) * 2015-09-30 2018-10-16 Deutsches Krebsforschungszentrum compound and pharmaceutical composition
MX2016008466A (en) * 2016-06-24 2017-12-25 Instituto Nac De Investigaciones Nucleares 99mtc-edda/hynic-ipsma as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen.
DE102016122273B4 (en) * 2016-11-18 2018-06-21 Abx Advanced Biochemical Compounds Gmbh Precursors for radiofluorination
PL3765097T3 (en) * 2018-03-16 2022-08-22 Universität Zu Köln 2-alkoxy-6-[18f]fluoronicotinoyl substituted lys-c(o)-glu derivatives as efficient probes for imaging of psma expressing tissues
CN109053862A (en) * 2018-08-07 2018-12-21 复旦大学附属肿瘤医院 Target PD-L1 polypeptide derivative and its99mThe preparation and application of Tc complex
PL239934B1 (en) * 2019-04-12 2022-01-31 Narodowe Centrum Badan Jadrowych Osrodek Radioizotopow Polatom Derivatives of PSMA inhibitors for ⁹⁹ᵐTc labelling by HYNIC, radiopharmaceutical kit, radiopharmaceutical preparations and their use in the diagnosis of prostate cancer
CN111253465A (en) * 2020-03-03 2020-06-09 复旦大学附属肿瘤医院 PSMA binding agent and application thereof

Also Published As

Publication number Publication date
AU2021229984A1 (en) 2022-10-27
CN111253465A (en) 2020-06-09
CN111777663A (en) 2020-10-16
CA3179523A1 (en) 2021-09-10
EP4011903A4 (en) 2023-09-20
EP4011903A1 (en) 2022-06-15
US20220315507A1 (en) 2022-10-06
CN111777663B (en) 2023-02-17
CN116284217A (en) 2023-06-23
WO2021175338A1 (en) 2021-09-10

Similar Documents

Publication Publication Date Title
AU2021229984B2 (en) PSMA combiner and use thereof
JP7194161B2 (en) Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and agents for the treatment of prostate cancer
CN111065646B (en) Radiopharmaceuticals
JP2022513256A (en) Dual Mode 18F Labeled Theranostic Compounds and Their Use
ES2844586T3 (en) 18F-tagged prostate specific membrane antigen (PSMA) inhibitors and their use as imaging agents for prostate cancer
EP3424940A1 (en) Radiolabeled drug
AU2020207081A1 (en) Conjugate comprising ligand and CEACAM5 antibody Fab fragment
EP3783016A1 (en) Modified antibody and radioactive metal-labelled antibody
WO2020210919A1 (en) Novel radiolabelled cxcr4-targeting compounds for diagnosis and therapy
JP2022507296A (en) Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptors (GRPR) and treatment of GRPR-related disorders
US6855308B2 (en) PACAP compositions and methods for tumor imaging and therapy
EP4232459A1 (en) Novel cxcr4-targeting compounds
AU669219B2 (en) Novel technetium and rhenium binding bivalent haptens, application to in vivo diagnostic and therapeutics, kits and immunological reagents used in combination
US20090304586A1 (en) Chelating Agent Conjugated Alpha-MSH Peptide Derivatives, Preparation Method Thereof and Composition for Diagnosis and Treatment of Melanoma Comprising the Same as an Active Ingredient
RU2730507C1 (en) Compound for diagnosing tumours expressing psma and composition based thereon
WO2024046469A1 (en) Cyclic peptide and preparation method therefor, and complex comprising same and use thereof
WO2023164775A1 (en) Radiolabeled compounds targetng the prostate-specific membrane antigen
JP2023554079A (en) Ligands and their uses
CN117752824A (en) Pretargeted tumor immune probe, bioorthogonal preparation, kit and application
CN117377696A (en) Humanized antibodies labeled with beta-emitting nuclides

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SHIYA PHARMACEUTICAL, INC

Free format text: FORMER APPLICANT(S): SHANGHAI FO ZE MEDICAL TECHNOLOGY CO., LTD